Risk of infection associated with targeted therapies for solid organ and hematological malignancies
Inhibidors de punts de control; Everolimus; Ibrutinib
| Authors: | ; |
|---|---|
| Format: | Article |
| Status: | Published version |
| Publication date: | 2021 |
| Country: | España |
| Institution: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repository: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:11351/6653 |
| Online Access: | https://hdl.handle.net/11351/6653 http://hdl.handle.net/11351/6653 |
| Access Level: | Open access |
| Keyword: | Medicaments antineoplàstics Hematologia oncològica DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Hematologic Neoplasms Other subheadings::Other subheadings::/therapy CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents Other subheadings::Other subheadings::Other subheadings::/adverse effects COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::neoplasias hematológicas Otros calificadores::Otros calificadores::/terapia |
| _version_ | 1878733589322924032 |
|---|---|
| author | Ruiz Camps, Isabel |
| author2 | Aguilar-Company, Juan |
| author2_role | author |
| author_browse | Aguilar-Company, Juan Ruiz Camps, Isabel |
| author_facet | Ruiz Camps, Isabel Aguilar-Company, Juan |
| author_role | author |
| collection | Recercat. Dipósit de la Recerca de Catalunya |
| description | Inhibidors de punts de control; Everolimus; Ibrutinib |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_5922b1342bc64410c1908fde5e6f6a13 |
| institution | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| instname_str | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:recercat.cat:11351/6653 |
| publishDate | 2021 |
| publishDateSort | 2021 |
| publisher | SAGE Publications |
| publisherStr | SAGE Publications |
| reponame_str | Recercat. Dipósit de la Recerca de Catalunya |
| spelling | Risk of infection associated with targeted therapies for solid organ and hematological malignancies Ruiz Camps, Isabel Aguilar-Company, Juan Medicaments antineoplàstics Hematologia oncològica DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Hematologic Neoplasms Other subheadings::Other subheadings::/therapy CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents Other subheadings::Other subheadings::Other subheadings::/adverse effects COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::neoplasias hematológicas Otros calificadores::Otros calificadores::/terapia Inhibidors de punts de control; Everolimus; Ibrutinib Inhibidores de puntos de control; Everolimus; Ibrutinib Checkpoint inhibitors; Everolimus; Ibrutinib Higher risks of infection are associated with some targeted drugs used to treat solid organ and hematological malignancies, and an individual patient’s risk of infection is strongly influenced by underlying diseases and concomitant or prior treatments. This review focuses on risk levels and specific suggestions for management, analyzing groups of agents associated with a significant effect on the risk of infection. Due to limited clinical experience and ongoing advances in these therapies, recommendations may be revised in the near future. Bruton tyrosine kinase (BTK) inhibitors are associated with a higher rate of infections, including invasive fungal infection, especially in the first months of treatment and in patients with advanced, pretreated disease. Phosphatidylinositol 3-kinase (PI3K) inhibitors are associated with an increased risk of Pneumocystis pneumonia and cytomegalovirus (CMV) reactivation. Venetoclax is associated with cytopenias, respiratory infections, and fever and neutropenia. Janus kinase (JAK) inhibitors may predispose patients to opportunistic and fungal infections; need for prophylaxis should be assessed on an individual basis. Mammalian target of rapamycin (mTOR) inhibitors have been linked to a higher risk of general and opportunistic infections. Breakpoint cluster region-Abelson (BCR-ABL) inhibitors are associated with neutropenia, especially over the first months of treatment. Anti-CD20 agents may cause defects in the adaptative immune response, hypogammaglobulinemia, neutropenia, and hepatitis B reactivation. Alemtuzumab is associated with profound and long-lasting immunosuppression; screening is recommended for latent infections and prevention strategies against CMV, herpesvirus, and Pneumocystis infections. Checkpoint inhibitors (CIs) may cause immune-related adverse events for which prolonged treatment with corticosteroids is needed: prophylaxis against Pneumocystis is recommended. The authors received no financial support for the research, authorship, and/or publication of this article. SAGE Publications https://hdl.handle.net/11351/6653 http://hdl.handle.net/11351/6653 |
| spellingShingle | Risk of infection associated with targeted therapies for solid organ and hematological malignancies Ruiz Camps, Isabel Medicaments antineoplàstics Hematologia oncològica DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Hematologic Neoplasms Other subheadings::Other subheadings::/therapy CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents Other subheadings::Other subheadings::Other subheadings::/adverse effects COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::neoplasias hematológicas Otros calificadores::Otros calificadores::/terapia |
| status_str | publishedVersion |
| title | Risk of infection associated with targeted therapies for solid organ and hematological malignancies |
| title_full | Risk of infection associated with targeted therapies for solid organ and hematological malignancies |
| title_fullStr | Risk of infection associated with targeted therapies for solid organ and hematological malignancies |
| title_full_unstemmed | Risk of infection associated with targeted therapies for solid organ and hematological malignancies |
| title_short | Risk of infection associated with targeted therapies for solid organ and hematological malignancies |
| title_sort | Risk of infection associated with targeted therapies for solid organ and hematological malignancies |
| topic | Medicaments antineoplàstics Hematologia oncològica DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Hematologic Neoplasms Other subheadings::Other subheadings::/therapy CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents Other subheadings::Other subheadings::Other subheadings::/adverse effects COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::neoplasias hematológicas Otros calificadores::Otros calificadores::/terapia |
| topic_facet | Medicaments antineoplàstics Hematologia oncològica DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Hematologic Neoplasms Other subheadings::Other subheadings::/therapy CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents Other subheadings::Other subheadings::Other subheadings::/adverse effects COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::neoplasias hematológicas Otros calificadores::Otros calificadores::/terapia |
| url | https://hdl.handle.net/11351/6653 http://hdl.handle.net/11351/6653 |